Sagar Patel, MD
Hematology & Oncology · Edina, MNNPI 1528327210
Payments from drug & device makers
Across 377 payments — averaging $1785.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$175K
- Incyte Corporation$172K
- National Marrow Donor Program$160K
- Gilead$121K
- Sanofi$10K
- CTI Biopharma Corp.$10K
- plus $24K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 111 | $175,407 |
| Incyte Corporation | 93 | $171,584 |
| National Marrow Donor Program | 13 | $160,226 |
| Gilead | 110 | $120,935 |
| Sanofi | 6 | $10,336 |
| CTI Biopharma Corp. | 2 | $10,195 |
| E.r. Squibb & Sons, L.L.C. | 3 | $6,540 |
| Stemline Therapeutics Inc. | 1 | $5,460 |
| Sobi, Inc | 2 | $4,324 |
| Medexus Pharma, Inc. | 4 | $2,381 |
| Gamida Cell Inc. | 5 | $2,191 |
| Bristol Myers Squibb | 5 | $705 |
| Mckesson Drug Company LLC | 1 | $610 |
| ZOLL Medical Corporation | 1 | $520 |
| AbbVie | 3 | $281 |
| Jazz Pharmaceuticals Inc. | 5 | $242 |
| Adaptive Biotechnologies Corporation | 2 | $205 |
| AstraZeneca | 1 | $200 |
| Amgen | 2 | $165 |
| Pharming Healthcare, Inc. | 1 | $139 |
| Kadmon Pharmaceuticals LLC | 1 | $133 |
| Karyopharm Therapeutics Inc. | 1 | $87 |
| Lilly USA, LLC | 1 | $39 |
| Siemens Medical Solutions USA, Inc. | 1 | $32 |
| Menarini Silicon Biosystems, Inc. | 1 | $23 |
| Rigel Pharmaceuticals, Inc. | 1 | $7 |
How this compares
$672,967 in reported general payments places this provider in the 85th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Edina
- Steven RouseyEdina$1.2M
- Ahmad RazaEdina$262K
- Shilpa GuptaMinneapolis$16.3M
- Yucai WangRochester$8.2M
- Daniel AndersonSaint Paul$7.3M
- Timothy LarsonMinneapolis$7.2M
- Yan JiSaint Paul$6.3M
- Manish PatelBloomington$6.2M
- Samith KochuparambilMinneapolis$3.3M
- Thomas AmatrudaFridley$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.